fa l l / w i n t e r 2 0 0 9
a growing concern: working to halt cancer’s spread Dr. Carol Swallow
a d va n c i n g s a r c o m a t r e at m e n t Pa s s i o n f o r R e s e a r c h a F a m i ly T r a d i t i o n
Letter from Leadership Jackie DeSouza Editor-in-Chief
Michael Power ed i t o r
Cecilia Mok a r t d i r ec t o r
Contributing writers: Frances Bartlett Melissa McDermott Allison Mullin Matthew Peltomaki Michael Power Emily Robb Catherine Shannon Photography: Sid Tabak Photography Inside Sinai welcomes your feedback. Please contact us: The Editor Inside Sinai Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex 341 – 600 University Avenue Toronto, Ontario m5g 1x5 t 416-586-5065 f 416-586-8555 CommunicationsandMarketing@mtsinai.on.ca
Inside Sinai is also available online at www.mountsinai.ca/about_us/publications. Inside Sinai presents an inside look at the people, innovations and research helping to make a difference in the lives of patients and their families. It is produced by the Mount Sinai Hospital Foundation. On the cover: The Sydney C. Cooper Program for the Prevention of Cancer Progression is a unique program of Mount Sinai Hospital that is bridging basic health research and clinical research. The result is hope for cancer patients whose disease has spread. Pictured on the cover is Dr. Carol Swallow, Surgical Oncologist and Clinical Scientist at Mount Sinai, who specializes in treating colorectal cancer. For the latest information on events and programs, please visit www.mountsinai.ca or www.mshfoundation.ca. To donate, please visit www.supportsinai.ca.
Medical research is changing rapidly. More and more, scientists and physicians are realizing the importance of working together towards improved outcomes for patients, as well as a greater understanding of health and disease. Collaboration between scientists and physicians often results in what is called “translational medicine,” meaning a research partnership that translates science into improved front-line care for patients. This issue of Inside Sinai reflects some of the newest and most exciting advancements at Mount Sinai Hospital and the Samuel Lunenfeld Research Institute — particularly in the field of health research. Translational medicine ensures that clinical information from patients informs basic lab research, and vice versa, resulting in a more rapid and beneficial transfer of basic science research to clinical applications. You can read about one of Mount Sinai Hospital’s truly translational medicine projects that is supported by philanthropy on page 10. And while this issue of Inside Sinai highlights some of the Lunenfeld’s most recent advances, it also reflects its rich history. On pages 8-9 you will find the story of how one family’s passion for research helped build one of the world’s leading research institutes. We know that you will find this edition both relevant and informative — research is the key to unlocking the mysteries of human health and disease, and we are proud of our researchers and doctors, who together are poised to transform health care as we know it. For more information about our initiatives, please visit our website at www.mountsinai.ca. To support our work and join our family of generous donors, please visit www.supportsinai.ca or call us at 416-586-8203. Sincerely,
Lawrence Bloomberg Chair, Board of Directors Mount Sinai Hospital
Joseph Mapa President and CEO Mount Sinai Hospital
Michael Bregman Co-Chair, Board of Directors Mount Sinai Hospital Foundation
Bob Rubinoff Co-Chair, Board of Directors Mount Sinai Hospital Foundation
Susan Horvath President Mount Sinai Hospital Foundation
In This Issue
Drs. Rebecca Gladdy and Jay Wunder are helping to build bridges between research and care in Mount Sinai’s Sarcoma Program.
f e at u r e s Passion for Research a Family Tradition
Growing Our Understanding of Cancer that Spreads
Samuel Lunenfeld played a pivotal role in expanding Mount Sinai and in the creation of the Hospital’s research facility. His family has continued that tradition, helping “the Lunenfeld” become one of the world’s best research institutes. Page 8
Metastatic cancer, or cancer that spreads to another part of the body, is often inoperable, and it usually cannot be cured through other treatments like chemotherapy or radiation. Work being done by Mount Sinai researchers aims to stop metastatic cancer in its tracks. Pa g e 1 0
Mount Sinai’s World-Renowned Sarcoma Program uses Research to Advance Treatment Led by Dr. Jay Wunder, physicians at Mount Sinai’s Sarcoma Program treat patients with cancers of the connective tissue. Their research has led to significant advances in the care sarcoma patients receive. Pa g e 1 6
fac e s
in the know
Mount Sinai’s Commitment to Excellence Resonates with Board Co-Chairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 A “Sweet Spot” for Young Scientists . . . . . . . . . . . . . . . . . 15 Supporting Healthy Pregnancies . . . . . . . . . . . . . . . . . . . . 18 Fabulous Philanthropy . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Notes from the Inside . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Photo Gallery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Ask the Expert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Notes from the Inside a w a rds & r e co g n i t i o n The American Thyroid Association (ATA)
Karen Muller, a Registered Nurse in Labour
Dr. Andras Nagy was profiled in the first-
awarded Dr. Paul Walfish the 2009 John
and Delivery, was one of three “Honourable
annual Scientific American Top 10 Honor
B. Stanbury Pathophysiology Award for his
Nominees” for The Toronto Star’s 2009
Roll. The only Canadian selected, Dr. Nagy
outstanding research contributions to the
Nightingale Award. The award is given each
shared the honour with U.S. President Barack
understanding of thyroid physiology and
year to a nurse who has touched patients’ lives.
Obama, Bill Gates, Michael Bloomberg and
thyroid disease. The award is given annually
Muller was nominated by a former patient.
other luminaries in the July 2009 issue of the magazine. In March 2009, Dr. Nagy revealed
to a researcher who has made a major impact on research or clinical practice. Dr. Walfish is
Dr. Daniel Durocher,
a new method of creating stem cells from
the first endocrinologist to win all three top
Principal Investigator at
adult cells that could lead to possible cures for
major awards for outstanding contributions to
the Samuel Lunenfeld
several devastating diseases, including spinal
thyroidology from the ATA.
Research Institute
cord injury, macular degeneration, diabetes
and Thomas Kierans
and Parkinson’s disease.
Neonatologist Dr. Connie Williams received
Research Chair in
the KJR Wightman Award for Scholarship in
Mechanisms of Cancer Development, was the
Two Mount Sinai
Ethics from the Royal College of Physicians and
2009 recipient of the Lloyd S.D. Fogler, QC,
psychiatrists won
Surgeons of Canada for her paper on the unique
Award of Excellence. The award is presented
teaching awards from
and challenging aspects of difficult decision-
annually to an investigator whose research
the University of
making in the NICU. The scholarship is awarded
has had a significant international impact.
Toronto’s Department
for the best scholarly paper presented by a
Dr. Durocher and his team discovered a new
of Psychiatry.
resident registered in a postgraduate program.
means by which cells communicate and repair
Dr. Paula Ravitz, above left, Psychiatrist and
damage to their DNA, giving insight into what
Acting Head of Mount Sinai’s Psychotherapy
goes wrong in cells that become cancerous.
Institute and Associate Head of the
Dr. Thomas Stewart became Mount Sinai’s
Psychotherapy Program for the University
Physician-in-Chief in July
Jason Macartney, a Respiratory Therapist in
of Toronto’s Department of Psychiatry, won
2009 and now holds
the Valentine Neonatal Intensive Care Unit
the Allan Tennen Award for Excellence in
the Sandra and Lionel
(NICU), won the Anderson Award from the
the Supervision of Psychotherapy.
Waldman Family Chair
University of Toronto’s Wightman-Berris
Dr. Sian Rawkins, above right, Psychiatrist
for the Physician-in-Chief. For the past 10
Academy in the Faculty of Medicine. The
and Head of Mount Sinai’s Ambulatory
years, Dr. Stewart has ensured excellent clinical
award honours the best teachers across all
Psychiatry Program, received the Rob
care, education and research in the Intensive
health disciplines from Mount Sinai and the
Hunter Award for Outstanding Achievement
Care Unit. He replaces Dr. Allan Detsky, who
University Health Network, which includes
in Postgraduate Education.
held the position for the previous 12 years.
Princess Margaret, Toronto Western and
events
Toronto General Hospitals.
Mount Sinai celebrated the grand opening of its new state-of-the-art
Mount Sinai came away a winner at the Hold ‘em for Life poker
Centre for Fertility & Reproductive Health on June 17, 2009. The
tournament, on April 23. Held at the Four Seasons Hotel, the event was
Centre, which includes expanded research space, an embryology lab
a tremendous success, drawing 300 participants and raising $850,000
and a viral program for patients infected with HIV and hepatitis B and
for equipment used for cancer care at Mount Sinai and Princess
C, is the largest full-service fertility centre in the Greater Toronto Area.
Margaret Hospitals. To date, Hold ‘em for Life has raised $2.5 million.
02 INSIDE SINAI
By allison mullin br e a k t hro u g hs Dr. Greg Ryan,
Dr. Sabine Cordes, Senior Researcher at the
In a study published in The Journal of
Maternal-Fetal
Samuel Lunenfeld Research Institute, and
Nutrition, Dr. Alexander Logan discovered
Medicine Specialist at
graduate student Angela Sing, along with
that the quality of a person’s diet can be
Mount Sinai, together
researchers at the Hospital for Sick Children
assessed through a test analyzing potassium
with Dr. Edgar Jaeggi
and the University of Toronto, made a
levels in their urine, providing a new and easy
at the Hospital for Sick
breakthrough in understanding how genes
way for physicians to check the overall quality
Children, successfully led a heart intervention
remember their past experience through
of their patients’ diets and help them improve
on an unborn baby. The medical team
Polycomb Response Elements, which are
long-term health.
inserted a needle through the mother’s
memory modules that switch genes on or
abdomen to expand the valve leading to the
off. The discovery may lead to insights into
Neonatologist Dr. Prakesh Shah and
baby’s aorta. Left untreated, the infant would
diseases such as schizophrenia and cancer.
colleagues released a study in the Canadian
have developed a lifelong cardiac condition
Medical Association Journal concluding that Dr. John Roder,
pregnant women who take multivitamin
Senior Investigator at
supplements had a reduced risk of giving birth
Dr. Katherine Siminovitch, Senior
the Samuel Lunenfeld
to babies with low birth weights. Low birth
Investigator and Sherman Family Research
Research Institute,
weight — 2.5 kilograms or less — increases
Chair in Genomic Medicine at the Samuel
developed a method to
the likelihood that infants will be admitted
prevent epilepsy caused
to the neonatal intensive care unit, need
and shortened lifespan.
Lunenfeld Research Institute, Director of The Fred A. Litwin Family Centre in
by a gene defect in mice, which may herald
multiple procedures, develop infections and
Genetic Medicine, Mount Sinai Hospital &
new therapies for those with the condition.
puts the infants at a higher risk of mortality.
University Health Network, and Director
The study was published August 3 in the US
of Genomic Medicine at the University
Journal Proceedings of the National Academy
Dr. John Kingdom, Maternal Fetal Medicine
Health Network, discovered a new genetic
of Sciences (PNAS) and gives evidence that a
Specialist and Rose Torno Chair in Obstetrics
pathway or road map that could provide
faulty version of a gene called Atp1a3 causes
and Gynaecology, discovered that the size
personalized treatment options for patients
epileptic seizures in mice. Also, Dr. Roder
of a woman’s placenta can determine
with a devastating liver disease called
and PhD candidate Bechara Saab discovered
whether her fetus is at a high risk of
primary biliary cirrhosis, offering hope to
a molecular link between intelligence and
stillbirth, and that if women are screened
those suffering with liver disease and other
curiosity. The scientists took a protein and
during pregnancy they can be treated
autoimmune diseases.
increased it by 50 per cent in a small area of
effectively and the risk of stillbirth can be
the brain called the dentate gyrus in mice. This
significantly reduced.
gave the mice superior memory in complex tasks and a significant increase in curiosity.
The 2009 Mount Sinai Hospital Classic Golf Tournament raised
The Mount Sinai Hospital Auxiliary Gala 2009 was held on May 14
$350,000 for cancer research at the Samuel Lunenfeld Research
at the Direct Energy Centre, Exhibition Place. The evening featured
Institute. Held on June 22 at Wyndance Golf Club, the event included
entertainment by legendary group Earth, Wind & Fire, and silent
live and silent auctions. In 15 years, the tournament has raised more
and live auctions. Funds raised at the event help fund the Auxiliary’s
than $2.5 million in support of groundbreaking research, patient care
$2-million Advancing e-Meds pledge.
and education at Mount Sinai Hospital. INSIDE SINAI 03
Photo Gallery Hold ‘em for Life Charity Challenge
2
3
Da Vinci Gala
1
5
4
6
1. Event Co-Chairs Tony Reale of BMO Capital Markets and Andrew Hoffman of Menkes Developments Ltd. at The Canadian Real Estate Industry Presents Play in Support of Cancer Research Hold ‘em for Life Charity Challenge on April 23. 2. Tony Reale and guests. 3. Edward Sonshine, Immediate Past Chair, Mount Sinai Hospital Foundation. 4. Dr. Paul Walfish, Endocrinologist and Senior Consultant at the Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases (centre) presents an award to Honourees, Ginetta and Ron Barbaro, on May 27 at the Da Vinci Gala.*
7
8
5. Da Vinci Gala Chair, Shellianne Bedder and Gala Honouree, Ron Barbaro.*
Leadership Sinai Recognition Event
6. Mildred Sonshine and Sandi Kirschner at the Gala.
George Knudson/Oakdale Pro-Am Golf Tournament Tribute Event
7. New Leadership Sinai member, Samantha Mizel, in front of her Leadership Sinai Disc at a recognition event on May 21.** 8. Members of the Leadership Sinai All-Star Cancer Research Team with Dr. Jim Woodgett (second from left), Director of the Samuel Lunenfeld Research Institute at the Leadership Sinai Recognition Event.**
9
9. L–R: Butch Mandel, Paul Brown, Susan Horvath, President, Mount Sinai Hospital Foundation and Brad Goldhar at the George Knudson/Oakdale Pro-Am Golf Tournament Tribute Event, hosted by Mount Sinai Hospital Foundation and Israel Cancer Research Fund on June 1.**
* Photo courtesy of Wendy L. Rombough. ** Photo by Francis Heraldo, Mount Sinai Hospital. *** Photo by AJ Messier Photography.
George Knudson/Oakdale Pro-Am Golf Tournament Tribute Event
Tony and Maggie Pawson Tribute Event
10
11
12
Founders’ Society Event
13
14
15th Annual Mount Sinai Hospital Classic Golf Tournament
15
10. L–R: David Lieberman, Susan Maldoff, Carole Zucker and Jack Winberg at the Oakdale Golf Tournament Tribute Event.** 11. L–R: Joseph Mapa, President and CEO, Mount Sinai Hospital; Dr. Jim Woodgett; Murray and Marvelle Koffler; and Dr. Tony Pawson at the Tony and Maggie Pawson Tribute Event on June 11.** 12. L–R: Larry Tanenbaum with Maggie and Tony Pawson.**
16
George Knudson/Oakdale Pro-Am Golf Tournament
13. L–R: Lawrence Bloomberg, Chair, Mount Sinai Hospital Board of Directors; Bob Rubinoff, Co-Chair, Mount Sinai Hospital Foundation Board of Directors; Susan Horvath; Brian Gluckstein, Chair, Founders’ Society; Michael Bregman, Co-Chair, Mount Sinai Hospital Foundation Board of Directors; and Joseph Mapa.* 14. Joseph Mapa and Sybil Kunin.* 15. Brian Gluckstein (middle) with Angelo and Carol DelZotto.*
17
16. Cheque presentation at the 15th Annual Mount Sinai Hospital Classic Golf Tournament, June 22. L–R (front): Susan Horvath, Co-Chairs Stephen J. Miller and Brian Cohen, Jonathan Pollack, Steven Hershenhorn, Jordan Sarick. L–R (back): Michael Bregman; Kenny Albert, Chair, Leadership Sinai; Joel Seigel and Shawn Mecklinger.*** 17. L–R: Joan Stevens, Vice-President, Donor Engagement, Mount Sinai Hospital Foundation; Dr. Harold Heft, Vice-President, Advancement, Mount Sinai Hospital Foundation; Dr. Allan Detsky, Past Physician-inChief, Mount Sinai Hospital; Susan Horvath; and Robert Harlang, CoChair, George Knudson/Oakdale Pro-Am Golf Tournament Committee.
Lunch with Leaders
18. L–R: Philip DeZwirek, Edward L. Greenspan (featured speaker) and Alan Mark at the Leadership Sinai Lunch with Leaders event on July 16.** 18
19
19. L–R: Mary Melanson, Lisa McDonald, Alyson Gampel, Shawn Saraga and Balti Sauer at the Leadership Sinai Lunch with Leaders.**
Photo Gallery continued Mount Sinai Hospital Auxiliary Gala
1
2
3
6
7
Drive fore a Cure Golf Tournament 1. L–R: The Mount Sinai Hospital Auxiliary Gala 2009 Co-Chairs Tom and Anna Koffler and Heather and Max Gotlieb. The Gala took place at Heritage Court, Direct Energy Centre on May 14. 2. The table of Gala Gold Sponsor, Bob Rubinoff/Inglewood Holdings Inc. Bob Rubinoff is in the back row, centre. 4
8
3. The table of Gala Gold Sponsor, GMP Securities LP. 4. Yoga In Motion took place at The Hangar, at Downsview Park on May 3, 2009.
Yoga In Motion
5. Yoga In Motion participants stretch for a cure.
Photos courtesy of Mount Sinai Hospital Auxiliary.
6. L–R: Judy Winberg, Murray and Marvelle Koffler, and Jack Winberg at the Drive fore a Cure Golf Tournament held on September 14 at Eagles Nest Golf Club. 7. L–R: Hedie Unger and Judy Winberg at the Drive fore a Cure Golf Tournament. 5
8. L–R: Paul Bura, Judy Wells, and Marilyn and Robert Cohen at the Drive fore a Cure Golf Tournament.
Mount Sinai’s Commitment to Excellence Resonates with Board Co-Chairs By michael power
M
ichael Bregman and Robert Rubinoff are on a mission. The two new Co-Chairs of the Mount Sinai Hospital Foundation Board of Directors are on a mission to enhance fundraising by broadening the donor base and holding signature events to support Mount Sinai’s patient care and research. Also, they aim to further build relationships with major donors, who support Mount Sinai and the Samuel Lunenfeld Research Institute so generously. “The culture of Mount Sinai, which is so dedicated to excellence, is one that resonates with me and makes me feel proud of my association,” says Bregman who, along with Rubinoff, was named Co-Chair of the Foundation Board on June 16. “I enjoy working with the people here. The senior executive of the Hospital has an open-door policy and works closely with the volunteer leaders.” Bregman, the Principal and Chief Executive Officer of Tailwind Capital Inc. and the former Chairman and CEO of Second Cup Ltd., has a long and successful history as an entrepreneur and community leader. He is Vice-Chair of Mount Sinai Hospital’s Board of Directors and has served in a leadership role on a number of Hospital and Foundation Boards and committees. He has also had active roles in several charitable organizations, including the United Jewish Appeal, Birthright Israel, and the University of Toronto’s Rotman School of Management. “One of the things I like most about working with Mount Sinai is that I’m always learning,” says Bregman, a triathlete who won a gold medal for Canada in the triathlon at the Maccabiah Games in Israel at the age of 51. “Mount Sinai remains for me a very interesting environment, even though I’ve been involved with the Hospital for quite some time.” Bob Rubinoff, an avid art collector, began his involvement with Mount Sinai when he became a member of the Hospital’s Board of Directors in 1982. He sat on the committee that oversaw the formation of the Samuel Lunenfeld Research
Board Co-Chairs Robert Rubinoff and Michael Bregman.
Institute, and has taken an interest in the Lunenfeld’s transformation from its smaller beginnings into a leading-edge research centre. “It was very interesting to watch the growth in the number of clinicians doing research,” Rubinoff says. “There was very little of that at the beginning. And to see the top doctors we’ve attracted because of the Lunenfeld is very exciting.” Rubinoff, President of Inglewood Holdings Inc., a private investment company, has contributed to numerous Hospital and Foundation Boards and committees. He also serves on the Board of the Huron College Foundation in London, Ontario. He donated $1.5 million to Right from the Start: Mount Sinai Hospital’s Campaign for Women’s and Infants’ Health, to support three triplet suites. Bregman and Rubinoff’s entrepreneurial spirit and history of leadership will stand them in good stead as they embark on their new mission at Mount Sinai. “Just to be around the Hospital and to see the quality of the people and the excellence of the Hospital itself have made me want to keep donating and raising money,” says Rubinoff. “I never stop learning new things here, and things are constantly changing. Just seeing what’s going on has inspired me for 27 years.” INSIDE SINAI 07
Passion for research a family tradition By frances Bartlett
w
hen Sybil kunin was a child, medical research was a popular topic around the family dinner table. “My father was fascinated with medicine,” she recalled. “He would talk about new research, new discoveries, and what equipment was needed.” Sybil’s father was Samuel lunenfeld, a steel magnate and real-estate developer who played a pivotal role in the expansion of Mount Sinai Hospital from its first location on Yorkville avenue to University avenue, and in the creation of the research facility that bears his name: the Samuel lunenfeld research institute of Mount Sinai Hospital.
L–r: georges hania, Barbara hania, Michael Benzie, norman Benzie, Sybil Kunin and the late reuben Kunin.
Photos courtesy of the Kunin family.
Mitchell and Silvana Kunin
08 inSiDE Sinai
Mr. lunenfeld grew up during the Great Depression, and he didn’t have the opportunity to attend university. “He was very successful, but i think he always regretted not having had more education,” said Sybil. The experience informed Mr. lunenfeld’s philanthropy; he gave generously to education and research throughout his life. in the story of Mount Sinai’s research facility he is known as “the guardian angel,” whose charitable foundation’s multi-million-dollar gift allowed the fledgling institute to take flight and soar.
Photos by John Loper.
“ i’m fascinated by what the lunenfeld scientists are doing. The link with the Hospital is so important; the researchers understand the needs of patients.” – BarBara Hania
This passion for research is a family tradition. Sybil and her husband reuben, who passed away in 2002, continued to give generously to the lunenfeld. Their son, Mitchell, is a long-time Board member, and their daughter, Barbara Hania, recently joined the foundation Board. Barbara’s husband, Georges Hania, is Vice-President in charge of financing of the Samuel lunenfeld Charitable foundation, and supervised its latest endowment gift of $7.5 million to the lunenfeld. “i’m fascinated by what the lunenfeld scientists are doing,” said Barbara. “The
link with the Hospital is so important; the researchers understand the needs of patients.” The family connection is something she treasures. “Going to the lunenfeld and seeing my grandfather’s name — it gives me a chill,” she says. “it’s wonderful that my father’s name lives on,” said Sybil, while touring the Orde Street labs with her daughter Michael and son-in-law norman Benzie. The institute known the world over simply as “the lunenfeld” is also known as one of the world’s best. Samuel lunenfeld would be proud. inSiDE Sinai 09
Cancer Metastasis:
Growing our Understanding of Cancer that Spreads
“F
rom the moment a patient receives a cancer diagnosis, he or she has to accept that they will likely face many challenges in the years ahead — even if their first tumour is removed successfully,” explains Dr. Carol Swallow, a Surgical Oncologist and Clinical 10 INSIDE SINAI
Scientist at Mount Sinai Hospital who specializes in colorectal cancer. “For many, the most devastating news they ever receive is that their cancer has spread, or metastasized,” Dr. Swallow adds, explaining that when a primary
colorectal tumour spreads — typically to the liver or lung — patient survival rates drop significantly. Sydney C. Cooper, one of Mount Sinai’s most dedicated friends, established the S.C. Cooper Sports Medicine Clinic in
L–R: Dr. Carol Swallow, Sydney C. Cooper and Dr. Jim Dennis in Mount Sinai’s Biospecimen Repository.
B y E m i l y R o bb the 1980s. In 2008, together with his family, he also established the Sydney and Florence Cooper Family Education Centre. Unfortunately he found himself in need of Dr. Swallow’s care about seven years ago. “I was diagnosed with colon cancer. Dr. Swallow removed my
first tumour successfully, and I thought I was fine. A few years later, I found out the cancer had spread, and reappeared in my lungs,” Mr. Cooper recalls.
be cured through other treatments like chemotherapy or radiation. For these reasons, most deaths from cancer are caused by the spread of the disease.
Metastatic cancer, like Mr. Cooper’s, is often inoperable, and it usually cannot
Luckily, Mr. Cooper’s lung cancer was operable and he has since fully recovered. INSIDE SINAI 11
In addition to being the world’s leading authority on a protein called gsk-3 that is directly implicated in cancer, Dr. Woodgett’s lab focuses on the two types of breast cancer tumours — one is known to spread and one doesn’t. His lab seeks to understand the genetic and cellular differences between these two types of tumours to better understand the mechanisms of metastatic cancer.
Purified tumour tissue DNA, in the final stages of processing, before being released for research studies.
From a statistical perspective, he was very lucky. But the terrible risk he faced when his cancer spread did not go unnoticed. He became concerned about how and why cancer spreads, and became committed to preventing it. “Because of my personal experience with cancer, I developed an interest in this area of research,” says Mr. Cooper. “I had a great respect for Dr. Swallow and her colleagues, and so I started making inquiries.”
A Project to Halt Cancer in its Tracks Mr. Cooper’s inquiries led him into discussions with Dr. Swallow and scientists at Mount Sinai’s Samuel Lunenfeld Research Institute, home to some of the world’s most renowned and acclaimed cancer researchers. The result was the establishment of the Sydney C. Cooper Program for the Prevention of Cancer Progression — a novel program that is now bridging the gap between basic health research, which uses science to expand our knowledge of disease and health at a fundamental level, and clinical research, which uses this knowledge to solve a particular medical problem (like metastasis, in this example). 12 INSIDE SINAI
Combining both basic and clinical research is also known as ‘translational research,’ which has become a pressing international priority in the last few years. In fact, never before has medical science been closer to applying laboratory science to solving human diseases. Through translational research, clinical information obtained from patients, pathology reports, and diagnostic lab tests can be invaluable in guiding laboratory research. Of equal importance, new knowledge arising in basic science laboratories can have a massive impact on health care delivery, ultimately resulting in a more rapid transfer of basic science discoveries into clinical practice. As fate would have it, when Mr. Cooper first approached Dr. Swallow, she was already working with Lunenfeld scientists. Dr. Jim Woodgett, Director of the Lunenfeld, is one of these scientists. “We know that most people who die from cancer actually die from metastatic spread of their initial disease,” he says. “This means that if we want to control or even cure cancer, we need to study how and why cancer spreads.”
“Metastasis is an incredibly complex process: a cancer cell needs to disengage from the original tumour, make its way into the bloodstream, travel through blood vessels, and reattach itself to a new part of the body that is actually a hostile environment for it. There is so much we need to know about this journey in order to interfere with it,” Dr. Woodgett reiterates. Dr. Jeff Wrana, Mary Janigan Research Chair in Molecular Cancer Therapeutics, is yet another world leader in this field. He studies proteins that affect the polarity (orientation) of cancer cells. These cells have a built-in sense of direction, but when they lose their polarity, they have essentially lost their bearings. They become confused, and are more likely to be disoriented — to “wander off” — and spread to other parts of the body. Figuring out what causes the loss of polarity will be an important clue to understanding cancer progression. When Dr. Swallow arrived at Mount Sinai, she joined the lab of Dr. Jim Dennis. Dr. Dennis is a Principal Investigator at the Lunenfeld and has been since the Institute was established in 1985. Dr. Dennis has been studying cancer metastasis for decades. One of his projects focuses on cancer cell metabolism. “Many cancer cells have an elevated metabolic capacity, which means they can consume more energy, grow more
“Mount Sinai Hospital is a fantastic place to conduct relevant translational research.”
Anita Patel, Research Technician, retrieves a tower containing fresh, frozen tumour tissue from a liquid nitrogen freezer in the Biospecimen Repository.
– dr. jim dennis
rapidly, and spread throughout the body more quickly,” he explains. Dr. Dennis’s lab also cloned a gene called Plk4, proved to be implicated in liver cancer. This gene promotes instability of the genome, which is a precursor to cancer progression and spread. While all of this basic research is critical to understanding the underpinnings of cancer’s ability to metastasize, it is incomplete without clues from patient samples and corresponding clinical data. Animal models of cancer were the typical study subject in Dr. Dennis’s lab, but “the arrival of Dr. Swallow really helped us focus on the human problems. She works with patients every day and sees scientific questions through that lens,” explains Dr. Dennis. He adds: “my lab has long been interested in cancer metastasis models in mice, but collaborating with Dr. Swallow, especially in relation to Plk4, enables us to be equally strong at exploring human cancer, too. And that has far greater implications for improving patient outcomes.”
Clinical Research Access to patient samples is another critical element of translational research. “We are very lucky at this Hospital to have a robust collection of patient tumour samples. The size and scope of our tissue databank is actually quite rare,” explains Dr. Swallow. The tissue samples stored within the databank hold much promise for research as they are INSIDE SINAI
accompanied by relevant clinical data about the patient, disease progression and outcomes. “Through tremendous collaboration and co-ordination with fellow surgical oncologists across Toronto who operate on both liver and lung tumours, we have managed to collect both primary and metastasized tumour samples from the same patient,” says Dr. Swallow. She adds that very few (if any) other centres in North America have access to such a rich source of research data. The tissue samples are stored in Mount Sinai’s Biospecimen Repository. In theory, comparing the genetic makeup and the relative activity of the genes in both the primary and secondary tumour samples of corresponding patients will shed a bright light on the key players that promote or delay the metastatic process. And if they can better understand the process, researchers will be better able to interfere with and stop cancer from spreading altogether. The Plk4 gene is a perfect example. Together, Dr. Dennis and Dr. Swallow will use basic science screening methodologies to analyze actual patient tumour samples to see how this gene contributes to the growth and spread of liver cancer.
The Results Mount Sinai’s expertise in the field, proven track record, and access to unique patient samples inspired Mr. Cooper to make his $1-million gift in 2008 to create the focused research program that is now being led by Dr. Swallow. The Sydney C. Cooper Program for the Prevention of Cancer Progression provides the opportunity for bright scientific and medical minds to join together in studying the fundamental 14 INSIDE SINAI
mechanisms of metastatic spread from a variety of disease perspectives. “Mr. Cooper’s investment in this program has launched an important, translational research study that unites basic and clinical research. His support has formalized what were previously informal collaborations; it has inspired new lines of inquiry and discovery, and propelled our work to the next step,” says Dr. Woodgett. Adding to this sentiment, Dr. Dennis explains that “Mr. Cooper’s contribution to our translational research efforts has strengthened the links between basic and human science, which should help us demystify the metastatic process more quickly.” “In the first year alone,” explains Dr. Swallow, “we have identified 16 patients for whom we have clinical data and tumour samples. Armed with this important information, I can now work with my colleagues at the Lunenfeld to sequence and analyze the gene expression, looking for clues that will help us understand how and why the cancer cells spread.” “I am fortunate for this opportunity to work with such motivated scientists at the Lunenfeld. Integrating clinical and basic research gives me great hope for my patients,” Dr. Swallow adds. Mr. Cooper remains involved in the program, tracking the work. “I am very pleased by the progress that is being made,” he says. “I am proud that my donation is supporting integrative approaches to the fight against cancer that will make a real difference.” To donate to research at Mount Sinai Hospital, please contact Marilyn Brown at 416-586-8203 ext. 6095, or mbrown2@mtsinai.on.ca.
It’s no wonder that a hospital with a reputation for lifelong caring also has the most complete fertility care. Please visit www.mountsinai.ca/fertility to learn more.
PhD candidate Kelly Seto is grateful for the bursary she received for her work in Dr. Irene Andrulis’s lab. She is the only Lunenfeld trainee investigating familial ovarian cancer. “I’m thankful to be in the presence of such gifted researchers who care so much about their students,” says Seto. “Nowhere else could I experience such a strong link between what happens in the lab and its application to hospital care.” Seto’s sentiments are echoed by colleague Ian Taylor, a PhD candidate and bursary recipient working under Senior Investigator Dr. Jeff Wrana. Taylor’s contribution to the development of ‘DyNeMo’ — an advanced diagnostic tool for breast cancer patients — has moved his career into the fast lane. He describes the Lunenfeld as a “sweet spot” for Canadian research, noting its small size, enthusiastic mentors, and donor support.
“Research institutes need to keep the best people in science, and thanks to donor support, the Lunenfeld is showing how to do it.” – n a d i n e k o l a s , pos t doc t o r a l f e l l o w
Kelly Seto and Nadine Kolas
A “Sweet Spot” for Young Scientists B y C at h e r i n e S h a n n o n
E
very year, more than 200 talented trainees collaborate with some of the brightest stars in biomedical science, in labs at the Samuel Lunenfeld Research Institute. Within three of these labs, three young scientists have made significant strides towards redefining the diagnosis, treatment and prevention of cancer. All three are quick to praise the support of the Research Training Centre (RTC ). It’s the go-to resource for research trainees when beginning their program, applying for funding, and preparing for the workforce. Legacy gifts are helping to provide new investigators with financial support and a boost to their confidence. When Doris Mack made a gift in her will to support trainees, she was not only honouring her late husband, Harold, but also helping influence the future of how we practise medicine.
Donations not only fund research, says Taylor, but also help investigators pay for grant applications that have the potential to attract even greater funding to the Lunenfeld. Postdoctoral fellow Nadine Kolas was drawn to the Lunenfeld following her graduate studies in New York. She has worked in Dr. Daniel Durocher’s cell biology lab for the past four years. Kolas and her colleagues recently discovered two new genes that help cells avoid cancer-causing mutations. She appreciates the RTC and its support of trainees — especially now that she hopes to start her own lab. Whether awarding bursaries or ensuring trainees receive a competitive wage, the RTC is working to reduce the burden on young scientists. “It can be tough starting out — especially financially,” explains Kolas. “Research institutes need to keep the best people in science, and thanks to donor support, the Lunenfeld is showing how to do it.” To share your legacy story, or to find out how you can make a difference in the future through a gift in your will, please contact Yolanda Bronstein at 416-586-8203 ext. 2963, or ybronstein@mtsinai.on.ca. INSIDE SINAI 15
Mount Sinai’s World-Renowned Sarcoma Program uses Research to Advance Treatment by melissa mcdermott
T
ammy Nickle and Mark Stewart feel fortunate for the outstanding care they receive from Dr. Jay Wunder, Surgeon-inChief and Orthopaedic Surgeon with Mount Sinai’s Sarcoma Program at the Christopher Sharp Centre for Surgery & Oncology. “Dr. Wunder has given me the best care I’ve ever had in my life,” says Nickle, who was diagnosed with Ewing sarcoma in 2007. Dr. Wunder removed the tumour from her leg, fitting her for an implant that spared her limb and allows her to bend her knee to 90 degrees and walk without a limp. “I wouldn’t trust anyone else with my leg.” Similarly, Mark Stewart, who was diagnosed with osteosarcoma in the 1990s (the same kind of tumour that afflicted Terry Fox), is impressed with Dr. Wunder’s patient care. “His unbelievable care and friendly nature are unsurpassed. I see Dr. Wunder once a year for a check up. He is always interested in me not only as a patient, but what I’m doing in my life.” Sarcomas are cancers of the connective tissue, such as that of the bone, cartilage or fat. There are two main types: those that arise from bone and cartilage, of which osteosarcoma, chondrosarcoma and Ewing sarcoma are the most common; and soft-tissue sarcoma, which develops from tissues such as fat, muscles, tendons, blood vessels and nerves.
00 INSIDE SINAI
Drs. Rebecca Gladdy and Jay Wunder
Dr. Wunder specializes in bone and soft-tissue sarcoma in the extremities (arms and legs). Dr. Wunder, Leadership Sinai Chair in Surgery and Rubinoff/Gross Chair in Orthopaedic Oncology and an Associate Member of the Samuel Lunenfeld Research Institute, and his colleagues have built a world-renowned sarcoma program. The largest of its kind in Canada, with the highest patient volume and most complex cases, the program also performs clinical research that has resulted in significant advances in sarcoma care.
“ A big reason I decided to come to Mount Sinai is the amazing research support at this Hospital and the emphasis on translational research.” – d r . r e b e cc a G l a ddy, S u r g i c a l O n co l og i s t
Dr. Wunder’s team has made discoveries that have changed patient care dramatically. Previously, patients with soft-tissue sarcoma received radiation post-surgery. With limb-preserving surgery now at almost 95 per cent, long-term functional outcomes have become more important. Research, numerous studies and a randomized clinical trial conclude that patients do better long term when treated with radiation pre-surgery. This is now the standard of care for soft-tissue sarcomas throughout Ontario, and is gaining acceptance worldwide. “Clinical practice changes like this one are discovered at Mount Sinai because of our rich source of patient data,” says Dr. Wunder. “Our patients are extremely willing to share their medical
information and tumour samples for research. We started a patient database in 1989 and we’ve had almost 100 per cent voluntary participation. Because of our patients, we have an invaluable tool to measure quality of life post-surgery.” Dr. Wunder and the joint Mount Sinai Hospital-Princess Margaret Hospital sarcoma team are also studying Intensity-Modulated Radiation Therapy (IMRT ), a new three-dimensional radiation approach. Previously, patients with soft-tissue sarcomas in extremities needed radiation, commonly leading to skin-healing complications requiring additional surgeries, prolonged dressing changes that sometimes led to infection, bone fractures, and amputation. Dr. Wunder observed that the IMRT technique results in radiation being given with more precise localization, minimizing the risk of wound complications.
Research That Enhances Treatment While Dr. Wunder focuses on cancers in the extremities, Dr. Rebecca Gladdy, a Surgical Oncologist and Associate Member of the Lunenfeld, specializes in soft-tissue sarcomas in areas other than the extremities. Dr. Gladdy’s clinical practice and research focuses on softtissue sarcomas in the abdomen. Dr. Gladdy, the team’s newest member, was recruited to Mount Sinai from Memorial Sloan-Kettering Cancer Center in New York City in 2008. “A big reason I decided to come to Mount Sinai is the amazing research support at this Hospital and the emphasis on translational research,” explains Dr. Gladdy, who dedicates 80 per cent of her time to research. Treatment for soft-tissue sarcomas involves radiation followed by surgery to remove the tumour. Unfortunately, these tumours are likely to recur in the
same area. Dr. Gladdy and her colleagues focus on educating other doctors in Canada on how to improve their ability to diagnose soft-tissue sarcomas. “Research needs to enhance treatment further,” says Dr. Gladdy. “The goal is to stop tumours from growing so that recurrence is less common, provide patients with non-surgical options and to be more sophisticated in how we treat each subtype of soft-tissue sarcoma. Dr. Gladdy’s lab at the Samuel Lunenfeld Research Institute has created cell lines that will be used to examine and screen molecular changes in softtissue tumours. The goal is to discover subtype-specific, molecularly targeted therapeutics that can provide new treatment options unique to each type of soft-tissue sarcoma. “Almost 50 per cent of those with the disease do not survive,” says Dr. Gladdy. “There is an urgent need for more specific treatments that limit toxicity and morbidity.” Similarly, the direction of Dr. Wunder’s translational research is focused on discovering molecular changes to better predict patient outcomes, identify targeted drugs to help stop metastasis, and develop more specific treatments for different sarcoma types. The research progress Drs. Wunder and Gladdy and their team have made supports their commitment to exceptional patient care. “I have an open invitation to call Dr. Wunder with any concerns at any time,” says patient Mark Stewart. “He’s the best doctor.” Join us in supporting research at Mount Sinai. Call 416-586-8203 or visit www.mshfoundation.ca. INSIDE SINAI 17
J Supporting Healthy Pregnancies: Mount Sinai’s Placenta Clinic
oy Tseng was 24 weeks pregnant when she learned that her baby was smaller than normal for that age. When an ultrasound didn’t determine the reason for the abnormally slow growth, Tseng was referred to Mount Sinai Hospital’s Placenta Clinic. There, she met the Clinic’s Director, Dr. John Kingdom, Maternal-Fetal Medicine Specialist at Mount Sinai and Rose Torno Chair in Obstetrics and Gynaecology. Tests revealed that Tseng’s placenta was not functioning properly, causing her baby to get insufficient nourishment from her blood. Around the same time, she developed high blood pressure, a condition she had never had before. At 30 weeks, Tseng still had high blood pressure and her baby remained small. She was induced due to concerns over her health. Sadly, the baby was stillborn.
by michael power
“We were devastated,” says Tseng. She and her husband, David Lau, named their first child Matthew. “But I still remember Dr. Kingdom reassuring me that the problem was the placenta and that it sometimes happens with first pregnancies. He told me that I was still young and I would be able to have children later on. He said that next time, they would monitor me closely.” The placenta connects the fetus to the uterine wall and extracts oxygen and nutrients from the mother’s blood, delivering it to the baby. The organ also removes toxins and carbon dioxide from the fetus and sends them back to the mother. Several common problems associated with the placenta can arise during pregnancy. One such complication is a potentially severe form of pregnancy-related hypertension — called preeclampsia — that affects the health of both mother and infant. Tseng’s hypertension never developed into pre-eclampsia, although doctors watched for signs of the condition during her pregnancy.
Dr. John Kingdom
18 INSIDE SINAI
Fetal growth restriction, another placenta-related condition, occurs when the placenta does not function well enough to allow the baby to grow properly. Invasive placenta (or placenta percreta) involves the placenta growing into the wall of the uterus. Fetal death or stillbirth (when the baby dies before delivery) is also related to placental function. Placental complications are common, and occupy roughly one quarter of the working time in fetal medicine.
“ we want to have our foot in the door at the lunenfeld so that we can contribute scientifically by providing placental material on the one hand, but we can also learn from the research done there.” – Dr. JOHn kinGDOM, M at e r n a l - f e ta l M e D i C i n e S P e C i a l i S t
“we recognized that abnormal placental development and damage can mediate several important diseases,” says Dr. kingdom. “rather than having a disease-focused clinic, we wanted to be organ-focused. we’ve modelled the idea largely on Mount Sinai’s Marvelle koffler Breast Centre, which treats a variety of breast problems. That Centre promotes breast health in its broadest sense, and we wanted to try to do the same thing with the placenta.” The Placenta Clinic gets referrals from across the Greater toronto area for pregnant women with placental complications. The Clinic is run from Mount Sinai’s Special Pregnancy Program. for the past 10 years, clinical hours on tuesdays have been devoted to caring for patients with placental complications.
This relationship can lead to discoveries that directly improve patient care. in a recent study, Dr. kingdom discovered that the size of a pregnant woman’s placenta can determine whether her fetus is at a high risk of stillbirth, and that if women are screened during pregnancy they can be monitored effectively to avoid the risk of stillbirth in potentially healthy babies. “we want to have our foot in the door at the lunenfeld so that we can contribute scientifically by providing placental material on the one hand, but we can also learn from the research done there,” Dr. kingdom says.
“ we want to help people by sharing our story and letting them know that there’s hope. for that kind of help, the Placenta Clinic is the best place there is.” – J O Y t S e n G , P at i e n t
The Placenta Clinic also taps expertise from across the Hospital, says Dr. kingdom. for example, a kidney or blood specialist may be called to help treat women with specific complications. “we can involve the full breadth and depth of Mount Sinai Hospital for patients who have placenta problems,” Dr. kingdom says.
when Joy tseng became pregnant again, she quickly contacted the Placenta Clinic. a placenta function test and an ultrasound revealed that her placenta was performing properly, and she returned regularly for ultrasounds and to ensure proper blood flow through the placenta. as well, the Clinic checked the size of her baby.
Until recently, Mount Sinai had been the only north american hospital with clinical hours dedicated solely to dealing with conditions of the placenta, Dr. kingdom says. But faculty members from the University of California, San Diego Medical Center visited the Hospital to study the Placenta Clinic, and that hospital opened its own version of the clinic on July 1, 2009.
in 2005, tseng gave birth to a son, luke, and in 2008 the couple had their second child, a daughter named lauren. “after we lost our first baby, i remember Dr. kingdom sitting down by my bedside and saying that one day soon i would have healthy babies,” recalls tseng. “when you’re going through a loss, you can’t think that far ahead. But looking back, i realize that what he said was right. So we want to help people by sharing our story and letting them know that there’s hope. for that kind of help, the Placenta Clinic is the best place there is.”
The Placenta Clinic also benefits from research done at Mount Sinai’s Samuel lunenfeld research institute. The Clinic provides the lunenfeld with placentas for research, while also learning from research into placental function done at the lunenfeld. The research institute houses a major genetic program that focuses part of its research efforts on the placenta.
To support women’s and infants’ health at Mount Sinai, please contact Marilyn Brown at 416-586-8203 ext. 6095, or mbrown2@mtsinai.on.ca. inSiDE Sinai 19
Canada’s most vulnerable babies depend on us.
Can we depend on you? We need your help to care for more than a thousand critically ill babies each year. Our Right from the Start campaign allows us to offer the best in pre-natal care, hope in high-risk pregnancies, and a fighting chance to fragile premature babies. Visit supportsinai.ca or call 416-586-8203 to donate and make a difference to the lifelong health of women and vulnerable infants.
Fabulous Philanthropy Help for Mount Sinai’s Highest Priorities
Peggy and Phillip DeZwirek
By Frances Bartlett
W
hen Phillip and Peggy DeZwirek decided to donate $1 million to Mount Sinai Hospital, their generosity went well beyond the monetary value of their gift. After considering an array of options for which their gift could be designated, the DeZwireks chose to support Mount Sinai’s highest priorities. “We looked at a number of alternatives, but in the end we figured that the Hospital itself would know best where the money was needed,” said Mr. DeZwirek. Indeed, Mount Sinai’s highest priorities are just that: representing the urgent need to continuously update technology and equipment and attract the very best medical and research talent. Transformational gifts like the DeZwireks’ help the Hospital to maintain its exceptional standards of excellence and its preparedness to meet the challenges of public health crises like SARS and now h1n1 . These standards, along with the superb care they have received as patients of the Hospital, inspired the DeZwireks’ support. “Mount Sinai was the leading authority in Ontario during
SARS ,” said Mr. DeZwirek, a private investor. He and his
wife, a retired investment banker, describe their gift as “a long-term investment for our community, for our children and our grandchildren.” The couple feels strongly that their investment was a wise choice. “Mount Sinai is an enormous resource for the community, not only for current medical and health care issues, but as a scientific research facility,” says Mr. DeZwirek. “We’ve received emails detailing the great medical breakthroughs made recently.” A plaque on the Hospital’s 4th Floor, dedicating the space as the “Phillip and Peggy DeZwirek Family Mezzanine,” quietly signals the couple’s generous contribution. “It is money well spent,” says Mr. DeZwirek. “Whatever you give is money well given and well utilized by the Hospital. There are great returns on whatever you invest in Mount Sinai.” Join us in supporting Mount Sinai’s highest priorities. Call 416-586-8203 or visit www.mshfoundation.ca. INSIDE SINAI 21
Donors Embrace New Venture
By Frances Bartlett
for medical research. The result was Venture Sinai, a new group dedicated to applying its skills to raising money. “The idea was to invite a critical mass of new donors, each making a five-year commitment in support of Mount Sinai and the Samuel Lunenfeld Research Institute,” says Rosenthal. The group, which held its inaugural meeting in May of 2009, would gather in a relaxed social setting, listen to a few select research presentations, decide where they wanted to ‘invest’ their donation, and then track the progress of that investment. “The response was phenomenal,” says Rosenthal, who ended up successfully recruiting 17 members to the group. “The people I contacted recognized that, by joining Venture Sinai, they could be part of something innovative and enjoyable, and at the same time have a significant impact at Mount Sinai.” This intersection of philanthropy and investment has inspired the creation of Venture Sinai Women. “Our group will support projects, research and clinical care that impacts women,” say Co-Chairs Camille Dan, Lisa Draper and Sheryl Salter. “After choosing a project to support, our members will maintain an ongoing involvement in the process and track the success of their investment.” Response to Venture Sinai Women has been overwhelming. “People are really attracted by the prospect of joining a small group of like-minded philanthropists that offers the opportunity to engage and learn,” add the Co-Chairs.
L–R: Venture Sinai Women Co-Chairs Lisa Draper, Sheryl Salter and Camille Dan.
E
arly in 2009, Mount Sinai Hospital Foundation board member Jeff Rosenthal wondered what would happen if he applied an investor’s approach to fundraising
22 INSIDE SINAI
The momentum of Venture Sinai is indicative of a growing trend in philanthropy. “More and more, our donors want to make a meaningful connection with the scientists and clinicians they support,” says Susan Horvath, President, Mount Sinai Hospital Foundation. “They want to be partners in our success.” Rosenthal agrees: “I think that this is a philanthropic model that speaks to the interests and engagement of a new generation of donors.”
Photo by Danny Santa Ana, Mount Sinai Hospital.
Charlene Girt Knows Her Heroes By frances bartlett
H
eroes have been on Charlene Girt’s mind a lot lately. “I’m crazy about baseball and the Blue Jays” she says, “but, and I know this is a cliché, they can’t save lives. We make celebrities of the wrong people. Actually, it should be the people who have the ability to improve and even save your life.” Given her criteria, it’s no surprise that Charlene’s list of personal heroes is topped by Dr. Robin McLeod. Dr. McLeod, Head of Mount Sinai’s Division of General Surgery and the Angelo and Alfredo De Gasperis Families Chair in Colorectal Cancer and IBD Research, is responsible for two of Charlene’s surgeries.
The first, a life-saving surgery, which Charlene describes as “the super major four-hour one, aka, the ultra-low anterior resection,” was for colorectal cancer and involved complicated reconstructive surgery and an ileostomy; the second procedure reversed the ileostomy, significantly improving Charlene’s quality of life. Since 1999, Charlene has had six surgeries at Mount Sinai. Most people prefer to put their patient experiences behind them, however, Charlene cheerfully admits to being fascinated by hospitals, an interest she traces back to childhood. “I should have died at birth,” she says. “I weighed 3 pounds, 13 ounces, and in 1945 saving a baby that small was an exceptional accomplishment. I think perhaps my love of hospitals came from knowing this. Also, I just find hospitals really interesting and inspiring places. I especially like operating rooms. Amazing things happen there.” For this retired librarian, each medical encounter has opened up new avenues of discovery. Her pursuit of knowledge has led Charlene to take part in clinical studies and attend lectures by
Charlene Girt
clinician-scientists. She has visited many areas of the Hospital, including the Surgical Skills Centre and the Robotics Facility at the Samuel Lunenfeld Research Institute. She has woven the Hospital into the fabric of her life. It is, she says, one of her favourite places. “Whenever I walk up University Avenue and see Mount Sinai, it just makes me smile. It makes me very happy — and also very grateful. I really do love this wonderful Hospital with its truly amazing physicians, nurses, researchers and support staff.” Charlene has expressed her appreciation by becoming a Legacy Sinai donor. By leaving the Hospital a major portion of her estate and naming Mount Sinai Hospital Foundation as the beneficiary of her RRSP s, she knows that she will continue to support a cause that is very important to her. “I’m interested in anything that I can do to assist in supporting Mount Sinai’s tradition of excellence because it is an outstanding Hospital. It is absolutely the best. I can’t think of anywhere better to leave my estate. It’s very satisfying to know that this will happen.” To share your legacy story, or to find out how you can make a difference in the future through a gift in your will, please contact Yolanda Bronstein at 416-586-8203 ext. 2963, or ybronstein@mtsinai.on.ca. INSIDE SINAI 23
opening new channels of communication B y m at t h e w P e lto m a K i
“H
ello @mountsinai! i sent this from your CCU March 13th. Thx for taking such awesome care of me!”
it’s fewer than 140 characters, and it uses short forms common in texting, but this simple message — or “tweet” — sent by a patient was instantly seen by hundreds of people on twitter. Mount Sinai’s twitter feed started in October 2008 as a way for the Media relations team to communicate breakthrough findings but has since expanded. it’s just one of the new social media channels Mount Sinai Hospital foundation is using to communicate with the public. when a Mount Sinai researcher makes a breakthrough, the news is now shared with a growing group of online supporters who receive daily updates on both twitter and facebook. what makes these forums special is the opportunity for followers to immediately respond to news, ask questions, or make a com24 inSiDE Sinai
ment. “These are truly unique ways for the community and the foundation to interact with each other,” says Chris Carter, Director of annual Giving. “The ability to directly answer questions enables us to better inform the public about the important work being done at the Hospital.” Besides breaking news, these sites have also been utilized to promote events, recruit volunteers, and raise money. when former patient will wong wanted to show his gratitude to Mount Sinai for the life-saving treatment he received while battling thyroid cancer, he turned to facebook to begin a unique fundraiser to benefit the Hospital. for a minimum $20 donation, facebook users can have a photo shoot with wong, then use the photo as their facebook profile picture. Proceeds will be donated to Mount Sinai. The foundation promoted the campaign by posting will’s story and continually updating his progress. Members of Mount Sinai’s Scotiabank toronto waterfront Marathon team used the social media device of daily blogging
as they prepared for the September 2009 event. The blog provided an avenue for team members to post helpful training tips, gather support, share personal stories, and offer unique fundraising ideas. The population of Mount Sinai’s online communities has grown quickly over a relatively short time. More than 200 people have become fans of the Hospital on facebook, where a profile has been active since January 2009, and more than 1,000 followers receive daily updates on twitter. The same number of people have tuned in to Mount Sinai’s Youtube channel, which features several short, informative videos covering various topics, such as interviews with researchers, donor recognition events, and tips on how to stay healthy. Mount Sinai supporters can continue to count on these channels to provide them with convenient and immediate access to information from the Hospital. Become a friend and a follower of Mount Sinai. Visit www.mshfoundation.ca to find links to each of the social media sites.
ask the expert Q. a.
if you have a question for one of our experts, please email communicationsandmarketing@ mtsinai.on.ca
i HAVE HEARD THAT MOUNT SINAI HAs A BONE AND TIssUE BANK. CAN YOU sHED sOME LIGHT ON WHAT THE BONE BANK DOEs? nly se O d te nt U atie & irradialant le P Sing rocessedfor transp
The rachel and David rubinoff Bone and tissue Bank at Mount Sinai Hospital provides highquality bone and tissue products for procedures that involve replacing bone or cartilage.
bio-p tissue ptic an Ase d hum ate
Don
atio nov ue in m
s. co tiss ing ch n o lo g ie anc e Adv ll o g r a ft te her bel w.a cing tissue Advan ww innovation since ce la pla 1972 www.all ograftte chnolog
www.all ograftte chnolog
since 1972
ies.com plex
gies. com
1972 nolo gies. com
2
on since 197
ture pera 1 tem om #10001 at ro CTO Store Canada lth Store Hea at room temperature
ue innovati
graf ttech
tiss Advancing
www.allo
Donated bone and tissue can be used for sarcoma patients as well as for those with arthritis or injuries where a limb or joint is damaged. Ground bone can be used as “packing” to fill in a small defect within a bone. Surgeons can also replace damaged cartilage in knees with donated cartilage.
2
Before the surgery to replace a length of bone, a suitable piece of replacement bone is reserved. During the procedure, the surgeon removes the diseased bone or tissue from the patient, and then fits the processed bone into the missing section. The implanted bone is held in place with plates and screws.
2 e 197 sinc e 197 sinc vat onion inno vati inno tiss ueue tiss anc inging Adv anc Adv com
w.a
com gies.gies. nolonolo ttechttech grafgraf .allo.allo wwwwww
in ch n o lo anc Adv ll o g r a ft te
since innovation
72
9 ce 1
n sin
o vati inno sue ie s. co m g g tis
place label here
ttech nolo
Com lth l Hea pita Hos bovic nai f Le 1X5 nt Si Wol enue M5G Mou and ph ity Av nada Jose nivers io, Ca U ar 600 o, Ont 70 m nt ies.co Toro 586-88 58 6olog t 41 586-44 ttechn 6af f 41 .allogr w ww
ww
ies.com
www.allo graf
Advancing tissue innovation
Single Patient Use Only
Aseptic bio-processed & irradiated Donated human tissue for transplant
tissue Advancing
The facility uses tissue from both deceased and live donors. tissue from deceased donors comes through the trillium Gift of life network. Patients can donate live bone that is removed during procedures such as hip replacements. to ensure the donations are appropriate, live donors are screened in part with a psychosocial and medical questionnaire. The tissue is also tested for the presence of viruses and bacteria in the Department of Microbiology and then radiated. The bone is stored at -70 Celsius, and can be kept for up to five years. an evaluation is performed in the Department of Pathology and laboratory Medicine to confirm tissue suitability for use as a transplant.
72
9 ce 1
n sin
Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex 600 University Avenue Toronto, Ontario, Canada M5G 1X5 t 416-586-8870 f 416-586-4458 www.allografttechnologies.com
Health Canada CTO #100011
Unlike organ transplants such as the heart or kidney, a patient’s body will not reject transplants of bone or cartilage. This eliminates the need to match the donor’s bone or tissue “type” with that of the recipient. The Hospital has recently approved a rebranding and new growth strategy for The rachel and David rubinoff Bone and tissue Bank. now to be known externally as allograft technologies, the bone and tissue bank will be looking to provide sufficient quantities of state-of-the-art tissue products and services to the entire province of Ontario. Dr. David Howarth is a Staff Pathologist at Mount Sinai Hospital who has acted as the Medical Director of The Rachel and David Rubinoff Bone and Tissue Bank for 16 years.
inSiDE Sinai 25
“
FUNDRAISING FOR MOUNT SINAI SHOWED ME THAT I COULD HELP A PERSON IN NEED. I JUST NEVER THOUGHT IT WOULD BE MY DAUGHTER . When I was in labour with my daughter, Samantha, there were some complications. The news got even worse when we found out she had health problems. The stress. The not knowing. We were worried. But the nurses were so comforting and reassuring. The care we received was excellent. I have been raising funds for Mount Sinai for years and I always imagined that I was helping other people. It’s funny how it all comes
”
back in the end. It’s up to all of us to help each other.
Amy Stein, member of Leadership Sinai since 2005 & Samantha Roach, daughter
TO DONATE Mount Sinai Hospital Foundation of Toronto, 1001-522 University Avenue, Toronto, Ontario M5G 1W7 t 416-586-8203 www.mshfoundation.ca